Provectus Biopharmaceuticals
(OTC) PVCT
Provectus Biopharmaceuticals Financials at a Glance
Market Cap
$28.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$57.48K
Net Income (TTM)
-$5.62M
EPS (TTM)
-$0.01
P/E Ratio
-5.04
Dividend
$0.00
Beta (Volatility)
0.25 (Low)
Dividend
$0.00
Beta (Volatility)
0.25 (Low)
Price
$0.07
Volume
378,599
Open
$0.07
Price
$0.07
Volume
378,599
Open
$0.07
Previous Close
$0.07
Daily Range
$0.07 - $0.07
52-Week Range
$0.04 - $0.11
Estimated Earnings Date
May 13, 2026
Dividend
$0.00
Beta (Volatility)
0.25 (Low)
Price
$0.07
Volume
378,599
Open
$0.07
Previous Close
$0.07
Daily Range
$0.07 - $0.07
52-Week Range
$0.04 - $0.11
Estimated Earnings Date
May 13, 2026
PVCT News
5 of Last Week's Biggest Losers
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Provectus Biopharmaceuticals
Industry
Pharmaceuticals
Sector
Health CareEmployees
6
CEO
Edward V. Pershing, CPA
Website
www.provectusbio.comHeadquarters
Knoxville, TN 37932, US
PVCT Financials
Key Financial Metrics (TTM)
Gross Margin
96.76%
Operating Margin
-8867.49%
Net Income Margin
-9775.33%
Return on Equity
89.65%
Return on Capital
N/A
Return on Assets
-972.83%
Earnings Yield
-19.84%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$28.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
420.28M
Volume
378.60K
Avg. Volume
160.44K
Financials (TTM)
Gross Profit
$55.62K
Operating Income
-$5.10M
EBITDA
-$5.10M
Operating Cash Flow
-$2.59M
Capital Expenditure
$5.00
Free Cash Flow
-$2.59M
Cash & ST Invst.
$223.88K
Total Debt
$2.77M
Provectus Biopharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
-100.0%
Gross Profit
-$466.00
+99.5%
Gross Margin
0.00%
N/A
Market Cap
$28.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$4.69M
N/A
Employees
6
N/A
Net Income
-$1.29M
-13.2%
EBITDA
-$1.10M
-0.6%
Quarterly Fundamentals
Total Cash
$223.88K
-42.7%
Total Debt
$2.77M
+7.4%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$66.65K
N/A
Short Term Debt
$2.70M
+4.8%
Return on Assets
-9.73%
N/A
Return on Invested Capital
76.48%
N/A
Free Cash Flow
-$357.57K
+67.3%
Operating Cash Flow
-$357.57K
+67.3%